Pharos iBio Co., Ltd. (KOSDAQ: 388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
10,020
+420 (4.38%)
Sep 11, 2024, 3:00 PM KST
-57.09%
Market Cap 129.45B
Revenue (ttm) n/a
Net Income (ttm) -10.49B
Shares Out 12.92M
EPS (ttm) -818.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 158,484
Open 9,680
Previous Close 9,600
Day's Range 9,680 - 10,350
52-Week Range 8,330 - 23,850
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.